Claroid Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Claroid Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Claroid Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $1.1M Trade | TransData Nexus

Claroid Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antifungals Specialist · $1.1M Total Trade · DGFT Verified

Claroid Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 3 products in 3 therapeutic categories. Based on 31 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ketoconazole ($747.5K), Theophylline ($350.0K), Linagliptin ($47.4K).

Claroid Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Claroid Pharmaceuticals Private Limited pharmaceutical export portfolio — 3 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Claroid Pharmaceuticals Private Limited? — Company Overview & Market Position

Claroid Pharmaceuticals Private Limited, established on August 31, 2018, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24304GJ2018PTC103796. It operates as a non-government entity, focusing on the manufacturing of pharmaceutical formulations. The authorized share capital is ₹15,00,00,000 (₹15 crore), with a paid-up capital of ₹1,50,00,000 (₹1.5 crore).

The registered office is located at 13 Mill Officer S, Co. Op. H. Soc., Opp. Mill Owners Association, Navrangpura, Ahmedabad, Gujarat 380009. As of March 2026, the company employs approximately 27 professionals. The official website is claroidpharma.com.

What Does Claroid Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ketoconazole$747.5K 2Theophylline$350.0K

Product Portfolio — Top 3 by Export Value

Claroid Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ketoconazole	Antifungals	$747.5K	19	1.9%	10
2	Theophylline	Respiratory	$350.0K	7	2.2%	8
3	Linagliptin	Advanced Diabetes Medications	$47.4K	5	1.2%	8

Claroid Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $1.1M. The top category is Antifungals (65.3% of portfolio), followed by Respiratory (30.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Claroid Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Claroid Pharmaceuticals operates a manufacturing facility situated at S.No-217/P, Opp. Gurukul English School, Pirana, Daskroi, Gujarat 382425. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed.

3Key Leadership

The leadership team at Claroid Pharmaceuticals includes:

Rushin Baijubhai Desai: Whole-Time Director
Arpankumar Patel: Director
Ghanshyam Arjanbhai Patel: Director
Snehalkumar Hasmukhlal Soni: Whole-Time Director
Shailesh Arjanbhai Patel: Whole-Time Director

These individuals have been serving in their respective roles since the company's inception on August 31, 2018.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Claroid Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

As of March 2026, Claroid Pharmaceuticals has not publicly disclosed any regulatory filings, approvals, or market access statuses in the United States, European Union, United Kingdom, Australia, or Japan. The company's export activities, as per TransData Nexus proprietary trade data, are primarily focused on markets outside these regions.

2Emerging Markets

Claroid Pharmaceuticals has engaged in export activities to various emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's product portfolio, which includes antifungals, respiratory medications, and advanced diabetes medications, aligns with the healthcare needs prevalent in these regions. While specific details regarding WHO prequalification are not publicly available, the company's export activities suggest a strategic focus on expanding its presence in emerging markets.

3Geographic Strategy

The company's export data indicates a concentration in specific therapeutic categories, with antifungals comprising 65.3% of exports, respiratory medications 30.6%, and advanced diabetes medications 4.1%. This concentration suggests a strategic focus on these therapeutic areas, potentially mitigating risks associated with over-diversification. However, the lack of diversification in product categories may expose the company to market fluctuations within these segments.

Claroid Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, Claroid Pharmaceuticals has not publicly disclosed any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection histories. The company's export activities, as per TransData Nexus proprietary trade data, do not include shipments to the United States, indicating limited or no engagement with the U.S. market.

2WHO & EU GMP

There is no publicly available information regarding Claroid Pharmaceuticals' WHO prequalification status or EU Good Manufacturing Practice (GMP) certifications. The company's export data does not indicate shipments to markets requiring these certifications, suggesting that the company may not currently hold these accreditations.

3CDSCO & Indian Regulatory

Claroid Pharmaceuticals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers in Gujarat. The company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. Specific details regarding these licenses and approvals are not publicly disclosed.

Claroid Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the therapeutic categories of antifungals, respiratory medications, and advanced diabetes medications, Claroid Pharmaceuticals faces competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's export data indicates a focus on these segments, suggesting a competitive positioning within these markets.

2Key Differentiators

Claroid Pharmaceuticals' strategic focus on specific therapeutic areas—antifungals, respiratory medications, and advanced diabetes medications—allows the company to develop specialized expertise and potentially offer differentiated products in these segments. However, the lack of diversification in product categories may limit the company's ability to leverage opportunities in other therapeutic areas.

3Strategic Position

Currently, Claroid Pharmaceuticals appears to be concentrating on the manufacturing and export of generic pharmaceutical formulations, with a focus on specific therapeutic areas. There is no publicly available information regarding the company's engagement in specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services. The future outlook suggests a continued emphasis on its current strategic direction, with potential for expansion into other therapeutic areas or markets as opportunities arise.

Buyer Due Diligence Brief — Evaluating Claroid Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Claroid Pharmaceuticals has demonstrated a consistent track record in exporting finished pharmaceutical formulations, with a total export value of $1.1 million USD across 31 shipments. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach to its product offerings. While the lack of diversification in product categories may pose risks, the company's consistent export activities suggest reliability in its operations.

2Certifications to Verify

Importers should verify the following certifications when considering Claroid Pharmaceuticals as a supplier:

FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
WHO-GMP Certification: To ensure adherence to international manufacturing practices.
EU GMP Certification: To verify compliance with European manufacturing standards.

Frequently Asked Questions — Claroid Pharmaceuticals Private Limited

How many pharmaceutical products does Claroid Pharmaceuticals Private Limited export from India?

Claroid Pharmaceuticals Private Limited exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Ketoconazole ($747.5K), Theophylline ($350.0K), Linagliptin ($47.4K). Total export value is $1.1M.

What is Claroid Pharmaceuticals Private Limited's total pharmaceutical export value?

Claroid Pharmaceuticals Private Limited's total pharmaceutical export value is $1.1M, based on 31 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Claroid Pharmaceuticals Private Limited cover?

Claroid Pharmaceuticals Private Limited exports across 3 therapeutic categories. The largest are Antifungals (65.3%, 1 products), Respiratory (30.6%, 1 products), Advanced Diabetes Medications (4.1%, 1 products).

Get Full Claroid Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.